QSI QUANTUM-SI INC

Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024

(Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024.

Quantum-Si’s management team will provide updates on the Company’s evolving technology roadmap, emerging applications for protein sequencing and the expanding commercial opportunities that these innovations create.

A live question and answer session will follow the formal presentations.

EVENT DETAILS:

WHEN: Wednesday, November 20, 2024 | 10AM – 12PM EST

WHERE: Westin NY Times Square, 270 West 43rd Street, New York, NY, 10036

REGISTRATION LINK (both in-person & virtual*):

*In-person attendance is limited to invited research analysts and institutional investors only. All other guests are invited to view the live or archived webcast virtually on the Investor Relations section of Quantum-Si’s website at . The archived webcast will be available for at least 90 days following the event.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at or follow us on or .

EN
31/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUANTUM-SI INC

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 14, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Quantum-Si Highlights Major Technical Advances, Next-Generation Platfo...

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024. Quantum-Si’s Management team announced Platinum™ Pro, the Company’s evolution of Platinum, as well as Proteus™, the Company’s new cutting-edge proteomics platform of the future, that is now under development. “We are very excited to have this opportunity to unveil the rapid innovation that we have achieved at Quantum-Si over the ...

 PRESS RELEASE

Avantor to Distribute Quantum-Si’s Next-Generation Protein Sequencing™...

BRANFORD, Conn.--(BUSINESS WIRE)-- (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions. The distribution agreement enables Avanto...

 PRESS RELEASE

Quantum-Si to Develop Acceleration Platform and Advance Core Technolog...

BRANFORD, Conn.--(BUSINESS WIRE)-- (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si’s advanced single-molecule protein sequencing and detection technologies,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch